Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oglufanide disodium in chronic hepatitis C
ACTRN12607000418471Phase 2Completed
- Sponsor
- Implicit Bioscience
- Start
- Aug 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of oglufanide disodium in hepatitis C virus infection, sponsored by Implicit Bioscience. Primary endpoint: Percentage of patients with greater than 2-log reduction in viral load. Started Aug 2007; status: completed.
02
Drugs
oglufanide disodium
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12607000418471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000418471.